Skip to content

Clinical study of intestinal flora in the development of chronic hepatitis B and hepatitis B cirrhosis

Clinical study of intestinal flora in the development of chronic hepatitis B and hepatitis B cirrhosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400090990
Enrollment
Unknown
Registered
2024-10-17
Start date
2024-03-01
Completion date
Unknown
Last updated
2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B and hepatitis B cirrhosis

Interventions

Healthy control group:None
Hepatitis B cirrhosis group:None

Sponsors

Chinese People's Liberation Army Rocket Force Characteristic Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
26 Years to 84 Years

Inclusion criteria

Inclusion criteria: Chronic Hepatitis B and Hepatitis B Cirrhosis Group : ? Meets the diagnostic criteria of the "Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Edition)"; ? Has been infected with hepatitis B virus for more than six months; ? Signed an informed consent form, voluntarily participating in the study. Healthy Group: ? Individuals confirmed to be within the range of physical health through a health examination; ? Those who have signed an informed consent form and voluntarily participate in the study.

Exclusion criteria

Exclusion criteria: Chronic Hepatitis B and Hepatitis B Cirrhosis Group : ? Patients infected within 3 months; ? Received antibiotics within 3 months; ? Received probiotics and probiotics within 3 months; ? Co-infection with hepatitis C virus, hepatitis D virus, human immunodeficiency virus and other hepatitis; ? Concomitant hypertension, diabetes, obesity, obvious atherosclerosis, chronic kidney disease, history of gastrointestinal surgery, inflammatory bowel disease, irritable bowel syndrome, malignant tumors, autoimmune diseases, Parkinson’s disease, Alzheimer’s disease, and stroke; ?Mental illness; ? Pregnant or lactating women. Healthy Group: ? Those who do not pass the health examination; ? Patients infected within the past 3 months; ? Individuals who have received antibiotic treatment within the past 3 months; ? Individuals who have undergone probiotic therapy within the past 3 months; ? Those who have experienced diarrhea in the recent 3 months; ? Mental illness; ? Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Gut microbiota;

Secondary

MeasureTime frame
Complete blood count;liver function ;renal function;blood ammonia;four liver fibrosis markers;five hepatitis B markers;hepatitis B DNA quantification;infection indicators;Basic information;

Countries

China

Contacts

Public ContactChangzheng Li

Chinese People's Liberation Army Rocket Force Characteristic Medical Center

licz007@aliyun.com+86 189 1088 3642

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026